Loading data for NVCT — first visit, this takes a few seconds.

알림

Nuvectis Pharma Inc. (NVCT)

NasdaqCM: NVCT · 실시간 가격 · USD

23.56

+0.21 (0.90%)

종가 기준: Aug 21, 2026, 8:00 PM

23.56

+0.00%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

0.90% (1D)

데이터 없음

매수호가	16.46
시가총액	767.62M
매출 (ttm)	n/a
순이익 (ttm)	-30.27M
	-0.26
	-1.32
	n/a
	-24.54
P/B (ttm)	69.29
P/S (ttm)	n/a
실적 발표일	Nov 3, 2026

매도호가	28.92
거래량	191,127
평균 거래량 (20일)	314,945
시가	23.59
전일 종가	23.35
일중 범위	22.83 - 23.93
52주 범위	5.55 - 29.27
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

NVCT 소개

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its na...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 4, 2022

직원 수 16

상장 거래소 NasdaqCM

티커 NVCT

웹사이트 https://www.nuvectis.com

전체 기업 정보

재무 실적

2025년 Nuvectis Pharma의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -26.44M로, 39.17% 증가했습니다.

재무제표

어닝 서프라이즈

Nuvectis Pharma가 Aug 4, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.3 예상치 하회 -0.04, 및 0.00% 전년 대비 성장.

다음 실적 발표

Nuvectis Pharma Inc.의 실적 발표 예정일은 Nov 3, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

4일 전 · Zacks

Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.

3주 전 · Zacks

Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know

The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among ...

1개월 전 · Zacks

Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e...

1개월 전 · Zacks

What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?

Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors? Let's find out.

1개월 전 · InvestorsHub

Nuvectis Pharma shares slide after pricing $100 million discounted stock offering (NVCT)

Secondary offering priced well below previous closeNuvectis Pharma (NASDAQ:NVCT) shares dropped 25% in premarket trading on Tuesday after the clinical-stage biopharmaceutical company priced a $100 mil...

2 페이지 중 1

Nuvectis Pharma Inc. (NVCT)